As of the end of June, Hangzhou Tigermed Consulting (03347) had repurchased a total of 20.9635 million A-shares.
Tiger Pharmaceuticals (03347) announced that as of June 30, 2026, the company has repurchased 20,963,500 A-shares through a special securities account for share repurchases using concentrated bidding trading method, accounting for 2.4347% of the company's current total share capital and 2.8410% of the company's current total A-share capital. The highest transaction price was 42.78 yuan per share, the lowest transaction price was 38.22 yuan per share, and the total transaction amount was 824 million yuan (excluding transaction fees). This repurchase is in compliance with the company's share repurchase plan and relevant laws and regulations.
Hangzhou Tigermed Consulting (03347) announced that as of June 30, 2026, the company repurchased 20,963,500 A shares through the share repurchase special securities account in a centralized bidding trading manner, accounting for 2.4347% of the company's current total share capital and 2.8410% of the company's current A share total share capital. The highest transaction price was 42.78 yuan per share, the lowest transaction price was 38.22 yuan per share, and the total transaction amount was 824 million yuan (excluding transaction costs). This repurchase meets the requirements of the company's share repurchase plan and relevant laws and regulations.
Related Articles
ITC Properties (00199) acquires a land parcel in Nantong, Jiangsu worth 2 billion RMB, planning to develop a green smart computing center and related businesses.
US Stock Market Move | The pharmaceutical sector received another round of capital switching, with GlaxoSmithKline plc Sponsored ADR (GSK.US) rising nearly 5%.
KUAISHOU-W (01024): Initial investors intend to increase their investment in Beijing Kaleido by $2.028 billion.
ITC Properties (00199) acquires a land parcel in Nantong, Jiangsu worth 2 billion RMB, planning to develop a green smart computing center and related businesses.
US Stock Market Move | The pharmaceutical sector received another round of capital switching, with GlaxoSmithKline plc Sponsored ADR (GSK.US) rising nearly 5%.
KUAISHOU-W (01024): Initial investors intend to increase their investment in Beijing Kaleido by $2.028 billion.
RECOMMEND
